ReviewJournal of immunology research2021

Determining Factors in the Therapeutic Success of Checkpoint Immunotherapies against PD-L1 in Breast Cancer: A Focus on Epithelial-Mesenchymal Transition Activation.

Mariana Segovia-Mendoza et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.